yep:)
If its a BP.. we will probably never get the massive growth we are and will be experiencing with ENZC BUT it might not be a bad place to park some of the ENZC windfall (again, if all of those other factors check out, like how well run is the new company, financials etc.)
If its a medium pharma (they probably wouldn't be able to afford us:).. but if they somehow pulled it off.. then I would probably be all over it.
It amazes me.. (as an example).. how when it was first announced that Pfizer was going to be approved for a vaccine how little the needle moved:) I bring that up because 1. they are so HUGE.. and 2. at the time they were experiencing some troubles in the rest of their pipeline - that even though the potential revenue from a Covid vaccine was promising, the potential revenue was seen as simply plugging some holes at the time.
so its not a slam dunk:).. but something to consider.
Lastly, I'm hoping for a "Regeneron model" with ENZC where we grow by licensing out many, many indications to other companies. Imo if ENZC has the willpower to do this.. ENZC itself could grow into a BP. And THAT would be incredible:)
Market Data 
Markets 
AI
